Pulsenmore Ltd. (PLSM) 股票分析

公司概述

Pulsenmore Ltd. operates within the Healthcare sector, specifically targeting the Medical Devices industry, where it specializes in providing self-scan ultrasound devices designed for remote clinical diagnosis and screening across Israel and Europe. The company's core offering includes the Pulsenmore home ultrasound system, which functions as a handheld ultrasound cradle dock compatible with a patient's smartphone, alongside a mobile application for uploading diagnostic images. As of the latest data, Pulsenmore Ltd. has a total market capitalization of $23.41 million and employs a workforce of 58 individuals to support its operational model. These valuation and headcount figures indicate that the company is a small-cap entity with a relatively lean organizational structure, suggesting a focused business model that relies heavily on technological innovation rather than extensive physical infrastructure or large-scale distribution networks to capture market share in the remote diagnostics space.

财务健康

The company reports negative financial performance in terms of profitability, with Net Income (TTM) listed as N/A and Revenue (TTM) also recorded as N/A, while EBITDA stands at a significant negative figure of $-40,888,000. The substantial gap between the reported revenue figure (which is not quantified in the provided data) and the net income loss reveals a cost structure where operating expenses and overheads significantly exceed current revenue generation, resulting in an Operating Margin of 0.0% and a Profit Margin of 0.0%. Additionally, the company's Gross Margin is recorded at 37.4%, indicating that while the core product pricing maintains a substantial portion of revenue above the cost of goods sold, this does not translate to bottom-line profit due to high operational costs. The Free Cash Flow for the trailing twelve months is $-19,023,376, which signifies a lack of financial flexibility and a reliance on external capital sources to fund day-to-day operations and strategic initiatives. Regarding the balance sheet, both Cash and Debt are listed as N/A, yet the Debt to Equity ratio is reported at 2.17, suggesting a leveraged capital structure where liabilities are more than double the equity base despite the absence of quantifiable debt figures in the dataset. The Current Ratio is an exceptionally high 7.98, which indicates robust short-term liquidity and a strong ability to meet short-term obligations with current assets, even in the presence of negative operating cash flow. Finally, the Return on Equity is -45.9% and the Return on Assets is -19.0%, metrics that reveal management is currently generating negative returns on shareholder investments and asset base, reflecting the challenges of scaling a loss-making business model in the medical device sector.

估值评估

Valuation metrics for Pulsenmore Ltd. are limited due to the absence of earnings data, with both the P/E Ratio (TTM) and Forward P/E listed as N/A, meaning traditional earnings-based valuation comparisons are not applicable at this time. Similarly, the Price to Book ratio and Price to Sales are both N/A, preventing a direct assessment of the market premium or discount relative to the company's book value or sales revenue. The EV/EBITDA is also N/A, further constraining the ability to value the company using standard enterprise value multiples. In terms of trading range, the stock has a 52-Week High of $10.28 and a 52-Week Low of $3.51, placing the current share price within a wide volatility band that reflects the uncertainty surrounding its future earnings trajectory. The Beta is recorded at 0.23, which indicates that the stock's price volatility is significantly lower than the broader market, suggesting it behaves more as a defensive or speculative instrument rather than a cyclical growth stock. These valuation characteristics imply that the market is pricing the stock based on potential future catalysts or specific niche utility rather than current fundamental earnings power or historical asset backing.

Growth & Income

Pulsenmore Ltd. is currently experiencing a contraction in its top line, with Revenue Growth (YoY) recorded at -8.1%, while Earnings Growth (YoY) is N/A due to the lack of positive earnings to compound. The decline in revenue suggests that the company is facing challenges in expanding its addressable market or retaining existing customers in the competitive medical device landscape. As the company does not pay dividends, indicated by a Dividend Yield of N/A and a Payout Ratio of 0.0%, it is not distributing cash to shareholders but instead retains all available capital, albeit negative in this instance, to fund operations and potentially invest in R&D or market expansion. The overall growth and income profile is characterized by negative revenue expansion and a complete absence of dividend income, reflecting a high-risk, high-reward investment scenario typical of small-cap biotech or medtech firms in a pre-profitability stage where cash burn is prioritized over shareholder returns.